March 1, 2018 / 8:05 AM / 8 months ago

BRIEF-Biohaven Announces Positive Results With Sublingual Rimegepant Zydis Orally Dissolving Tablet

March 1 (Reuters) - Biohaven Pharmaceutical Holding Company Ltd:

* BIOHAVEN ANNOUNCES POSITIVE RESULTS FROM BIOEQUIVALENCE STUDY WITH SUBLINGUAL RIMEGEPANT ZYDIS® ORALLY DISSOLVING TABLET

* ‍BIOHAVEN IS PLANNING TO INITIATE A PHASE 3 TRIAL WITH RIMEGEPANT ZYDIS(®) ODT IN Q1 OF 2018​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below